全文获取类型
收费全文 | 3236篇 |
免费 | 265篇 |
国内免费 | 87篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 72篇 |
妇产科学 | 79篇 |
基础医学 | 460篇 |
口腔科学 | 24篇 |
临床医学 | 137篇 |
内科学 | 486篇 |
皮肤病学 | 53篇 |
神经病学 | 101篇 |
特种医学 | 48篇 |
外科学 | 422篇 |
综合类 | 282篇 |
现状与发展 | 1篇 |
预防医学 | 225篇 |
眼科学 | 19篇 |
药学 | 550篇 |
5篇 | |
中国医学 | 118篇 |
肿瘤学 | 491篇 |
出版年
2024年 | 3篇 |
2023年 | 38篇 |
2022年 | 61篇 |
2021年 | 102篇 |
2020年 | 127篇 |
2019年 | 119篇 |
2018年 | 95篇 |
2017年 | 108篇 |
2016年 | 115篇 |
2015年 | 104篇 |
2014年 | 146篇 |
2013年 | 235篇 |
2012年 | 128篇 |
2011年 | 153篇 |
2010年 | 132篇 |
2009年 | 118篇 |
2008年 | 144篇 |
2007年 | 128篇 |
2006年 | 140篇 |
2005年 | 120篇 |
2004年 | 114篇 |
2003年 | 107篇 |
2002年 | 103篇 |
2001年 | 83篇 |
2000年 | 95篇 |
1999年 | 52篇 |
1998年 | 71篇 |
1997年 | 39篇 |
1996年 | 37篇 |
1995年 | 60篇 |
1994年 | 44篇 |
1993年 | 35篇 |
1992年 | 37篇 |
1991年 | 39篇 |
1990年 | 41篇 |
1989年 | 45篇 |
1988年 | 22篇 |
1987年 | 26篇 |
1986年 | 39篇 |
1985年 | 49篇 |
1984年 | 33篇 |
1983年 | 15篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 12篇 |
1979年 | 15篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 5篇 |
1973年 | 3篇 |
排序方式: 共有3588条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
V. Jenkins I. Solis-Trapala H. Payne M. Mason L. Fallowfield S. May L. Matthews S. Catt 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):99-107
Aims
Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.Material and methods
Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.Results
In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study.Conclusion
Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted. 相似文献5.
6.
7.
Eo Toriyama Tomoko Hata Kenichi Yokota Masahiko Chiwata Rena Kamijo Miki Hashimoto Masataka Taguchi Makiko Horai Masatoshi Matsuo Emi Matsuo Yumi Takasaki Yasuhisa Kawaguchi Hidehiro Itonaga Shinya Sato Koji Ando Yasushi Sawayama Jun Taguchi Yoshitaka Imaizumi Hideki Tsushima Tatsuro Jo Shinichiro Yoshida Yukiyoshi Moriuchi Yasushi Miyazaki 《Cancer science》2020,111(12):4490
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients. 相似文献
8.
复发性流产是一种常见妊娠并发症,病因复杂多样,其中内分泌因素占8%~12%,文章主要就甲状腺功能异常、高催乳素血症、多囊卵巢综合征及代谢异常、糖尿病、黄体功能不全等内分泌因素进行综述,旨在为复发性流产的预防及治疗方面带来新的思考。 相似文献
9.
Cathryn M. Kolka 《Clinical and experimental pharmacology & physiology》2020,47(1):168-175
The endocrine system relies on the vasculature for delivery of hormones throughout the body, and the capillary microvasculature is the site where the hormones cross from the blood into the target tissue. Once considered an inert wall, various studies have now highlighted the functions of the capillary endothelium to regulate transport and therefore affect or maintain the interstitial environment. The role of the capillary may be clear in areas where there is a continuous endothelium, yet there also appears to be a role of endothelial cells in tissues with a sinusoidal structure. Here we focused on the most common endocrine disorder, diabetes, and several of the target organs associated with the disease, including skeletal muscle, liver and pancreas. However, it is important to note that the ability of hormones to cross the endothelium to reach their target tissue is a component of all endocrine functions. It is also a consideration in organs throughout the body and may have greater impact for larger hormones with target tissues containing a continuous endothelium. We noted that the blood levels do not always equal interstitial levels, which is what the cells are exposed to, and discussed how this may change in diseases such as obesity and insulin resistance. The capillary endothelium is, therefore, an essential and understudied aspect of endocrinology and metabolism that can be altered in disease, which may be an appropriate target for treatment. 相似文献
10.